Micron Biomedical

Carousel - Homepage

Micron Biomedical Expands Leadership to Mobilize for Pivotal Studies and Commercialization of First Needle-Free Dissolvable Vaccines and Therapeutics

May 27, 2026

Micron Biomedical Celebrates the Grand Opening of Its Commercial-Scale Manufacturing Site in Georgia

May 21, 2026

Micron Biomedical Named to Fast Company’s 2026 List of World’s Most Innovative Companies for Addressing the Most Significant Bottlenecks in How Medicine is Made, Distributed and Administered

March 26, 2026

Emory University and Micron Biomedical Launch First-in-Human Clinical Trial of Next-Generation Rotavirus Vaccine Delivered via Dissolvable Microarray Technology

June 16, 2025

Micron Biomedical Names Health Education and Empowerment Advocate, Dr. Jayne Morgan, to Board of Advisors

June 9, 2025

Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics and Vaccines

January 16, 2025

Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without Needles

January 14, 2025

CEPI and Micron Biomedical Accelerate Needle-Free Vaccines against Disease X with $3.7 Million Grant to Advance Learnings from COVID-19

January 8, 2025

Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World’s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants

January 7, 2025

Micron Biomedical Recognized as a Breakthrough Scientific Innovation in the Prix Galien Start-Up Category

November 7, 2024

Micron Biomedical Wins the “Biotech Medical Innovation” Award at Boston Biotech Week

October 17, 2024